Evidence map›Paper›PMID 42649900›Full record

ReviewCancers2026

Giorgia Silvestrini, Serena Travaglini, Luca Guarnera, Nicole Lelli, Mariadomenica Divona, Elisa Casciani, Sara Ceccolini, Giulia Falconi, Tiziana Ottone, Maria Teresa Voso

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Two Decades ofCancers · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giorgia SilvestriniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Serena TravagliniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-5411-1502
Luca GuarneraPhD Program in Immunology, Molecular Medicine and Applied Biotechnology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Nicole LelliPhD Program in Immunology, Molecular Medicine and Applied Biotechnology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Mariadomenica DivonaDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Elisa CascianiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Sara CeccoliniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Giulia FalconiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-7699-1427
Tiziana OttoneDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-1936-3592
Maria Teresa VosoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-6164-4761

Funding

"Amici di Beat Leukemia Dr. Alessandro Cevenini" - ONLUSFondo Italiano per la Scienza (FIS3) FIS-2024-06156
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acute myeloid leukemiaallogeneic stem-cell transplantationallo-HSCTFLT3iFLT3 inhibitorsFLT3-ITDmeasurable residual diseaseMRDnext-generation sequencingNGS

Identifiers

PMID42649900
PMCPMC13511024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.